2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Value, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6023 A multidimensional emll scoring system for the diagnosis of EBV-associated post-transplant lymphoproliferative disorder

Xueying Wu, Man Chen2, Hui Wang IV, MD3
1 Hebei Yanda Lu Daopei Hospital, Langfang, China
2 Beijing Lu Daopei Hospital, Beijing, China
3 Hebei Yanda Lu Daopei Hospital, Langfang, China

Objective: To evaluate the diagnostic performance of the EMLL scoring system for Epstein–Barr virus (EBV)–associated post-transplant lymphoproliferative disorder (PTLD) and to investigate the distribution of EBV viral load across lymphocyte subsets. Methods: In this retrospective study, 5,041 patients undergoing allo-HSCT were screened, and 1,273 high-risk patients underwent flow cytometric detection of monoclonal B cells and/or plasma cells (MC B/P). A total of 209 patients (121 PTLD and 88 non-PTLD) were included for model development. Clinical and laboratory parameters, including EBV viral load, cytomegalovirus (CMV) viral load, detection of MC B/P by FCM, and lactate dehydrogenase (LDH) levels, were systematically collected and analyzed. The antibody panel included cytoplasmic κ fluorescein isothiocyanate (FITC), cytoplasmic λ phycoerythrin (PE), CD19 PerCP-Cy7, CD38 APC, CD20 APC-Cy7, CD56 BV421, and CD45 V500. Based on established criteria, at least 50 clustered monoclonal cells were required for detection, and a cutoff value of ≥0.1% MC B/P was defined as positive. Tissue and cerebrospinal fluid (CSF) samples were processed using similar procedures, with acquisition of all available cells in low-cellularity specimens. In addition, 64 patients underwent flow cytometric cell sorting to isolate B cells, plasma cells, T cells, and NK cells for subsequent assessment of intracellular EBV viral load. Sorting cells were stained with antibodies including CD38 FITC, CD22 PE, CD3 PerCP-Cy5.5, CD19 PerCP-Cy7, CD138 APC, CD20 APC-Cy7, CD7 BV421, and CD45 V500. EBV viral load was further assessed in sorted lymphocyte subsets in 29 PTLD patients. Multivariable logistic regression was used to identify associated factors and construct the EMLL score. Diagnostic performance was evaluated using ROC analysis. Results: 121 patients were ultimately diagnosed with EBV-associated PTLD, corresponding to an overall incidence of 2.4%. A total of 118 patients (9.3%) were classified as MC B/P-positive, including 61 patients (4.8%) with monoclonal B cells alone, 43 (3.4%) with both monoclonal B cells and plasma cells, and 14 (1.1%) with monoclonal plasma cells alone. The median proportion of monoclonal B cells was 0.3% (IQR, 0.10%–1.2%), while the median proportion of monoclonal plasma cells was 0.10% (IQR, 0.00%–0.3%).FCM-based detection of MC B/P demonstrated a sensitivity of 81.82%, specificity of 98.35%, positive predictive value of 83.90%, and negative predictive value of 98.10% for PTLD screening. Univariate analysis showed that lymphadenopathy/organomegaly, EBV load, CMV load, monoclonal B cells, monoclonal plasma cells, and LDH were significantly associated with PTLD (P < 0.05). Multivariable analysis identified lymphadenopathy/organomegaly and monoclonal B cells as independent factors. The EMLL score, incorporating EBV load (≥500 copies/mL), monoclonal B cells, monoclonal plasma cells, lymphadenopathy/organomegaly, and LDH, demonstrated excellent diagnostic performance with an AUC of 0.922, sensitivity of 91.7%, and specificity of 97.5%. Analysis of sorted lymphocyte subsets revealed that EBV viral load was significantly higher in B cells and plasma cells than in T cells, natural killer cells, and plasma. Conclusions: FCM-based detection of MC B/P in peripheral blood may contribute to earlier diagnosis of PTLD. The EMLL scoring system shows good diagnostic value. EBV viral load is higher in B cells and plasma cells than in plasma, T cells, and natural killer cells.

 

Hui Wang IV, MD: No relevant conflicts of interest to declare.